Core Viewpoint - The HPV vaccine, crucial for preventing cervical cancer in women, is gaining attention in China, with discussions on its inclusion in national immunization programs and local public health initiatives [1][6]. Group 1: Current Policies and Implementation - Sixteen provinces in China have introduced policies for HPV vaccination, with Beijing offering free vaccinations for eligible schoolgirls starting this autumn [2][3]. - The implementation plan in Beijing specifies the use of domestically produced bivalent HPV vaccines for girls aged 9 to 14, following a specific immunization schedule [2]. Group 2: Public Health Impact - HPV infection is responsible for 80-90% of cervical cancer cases, which ranks as the third most common cancer among women aged 15-44 in China [2]. - The call for government-funded vaccinations has been growing, with initiatives already covering over a million eligible girls in Jiangxi province [3]. Group 3: Challenges in Vaccine Accessibility - Economic disparities across regions pose challenges to the expansion of HPV vaccination programs, with approximately 42% of provinces offering free vaccinations [4]. - The average procurement price of HPV vaccines has decreased by 50-70% due to competitive procurement processes, which could enhance accessibility [4][5]. Group 4: Need for National Immunization Inclusion - Experts advocate for the inclusion of the HPV vaccine in the national immunization program to ensure equitable access for all children, regardless of their economic background [6][7]. - The World Health Organization has set a target for 90% vaccination coverage among girls aged 9-14 by 2030, highlighting the urgency for national policy changes [6][7].